Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/61826
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Multiple myeloma: Treatment evolution |
Autor: | San Miguel, Jesús F. CSIC ORCID; Mateos, Maria Victoria; Ocio, Enrique M. CSIC ORCID ; García-Sanz, Ramón | Fecha de publicación: | 2012 | Editor: | Taylor & Francis | Citación: | Hematology 17(Supl.1): s3-s6 (2012) | Resumen: | Melphalan-prednisone (MP) was introduced for the treatment of MM in late 1960s. In the subsequent 30 years, the treatment improvements remained stagnant, since more complex chemotherapy combinations, such as vincristine, doxorubicin, and dexamethasone (VAD), or with the addition of BCNU (VBAD) or melphalan and cyclophosphamide (VCMP), only led to small increases in the overall response rate but without differences in survival, as assessed in a large meta-analysis that included over 6000 patients. The next step forward was the use of high-dose melphalan followed by stem cell support (autologous stem cell transplant - ASCT) for young myeloma patients, which resulted in a significant improvement in disease free survival and overall survival. However, for elderly patients MP remained as the standard of care. From year 2000, a revolution in the treatment armamentarium of MM has emerged with the availability of new agents with singular mechanism of action such as thalidomide and lenalidomide (Revlimid®), both immunomodulatory drugs and the proteasome inhibitor bortezomib (Velcade®). | URI: | http://hdl.handle.net/10261/61826 | DOI: | 10.1179/102453312X13336169154971 | Identificadores: | issn: 1024-5332 e-issn: 1607-8454 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
16
checked on 21-abr-2024
WEB OF SCIENCETM
Citations
14
checked on 23-feb-2024
Page view(s)
303
checked on 24-abr-2024
Download(s)
99
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.